> MEDIA   Overview   Press Releases   Media Stories   Download Center   Video Gallery   Photo Gallery   Media Contacts

Press Releases 2017 2018 2019 2016 2015 2014 2013 2012 2011 2010 2009 2008 2007 2006 2005     December 2016 27 Dec  Journal of the American Medical Association  (JAMA) Publishes Mylan and Biocon's  Proposed Biosimilar Trastuzumab Phase 3  Data 09 Dec  Biocon Features in Asia IP Elite 2016 List   November 2016 29 Nov  Biocon's Novel Diabetes Education Initiative  for Medical Practitioners 'ABIDE' Awarded  by RSSDI 11 Nov  Biocon Collaborates with Healthcare  Professionals for a Public Awareness  Campaign on Diabetes Prevention &  Management Across India 08 Nov  Mylan and Biocon Announce U.S. FDA  Submission for Proposed Biosimilar  Trastuzumab 03 Nov  Mylan and Biocon Announce Regulatory  Submission for Insulin Glargine Accepted  for Review by European Medicines Agency   October 2016 28 Oct  Biocon Ranked Among Global Top Ten  Biotech Employers; The only Asian  Company to Feature in 2016 Rankings 20 Oct  Biocon Q2 FY17 Revenue Up 21%  EBITDA Up 45% Revenues at Rs 992 Crs.;  EBITDA at Rs 277 Crs.; Net Profit at Rs 147  Crs.   September 2016 19 Sep  Biocon Appoints Suresh Subramanian as  Head of Branded Formulations (India)  Business 01 Sep  Kiran Mazumdar Shaw Appointed 'Knight of  the Legion of Honour' by the Government of  France  August 2016 25 Aug  Mylan and Biocon Announce Regulatory  Submission for Proposed Biosimilar  Trastuzumab Accepted for Review by  European Medicines Agency   July 2016 28 July  Biocon Initiates "Ek Prayaas" Nationwide  Awareness Program on Hepatitis C 21 July  Biocon Reports a Strong Q1FY17  Revenues at Rs 952 Crore, up by 11 %;  EBITDA Up 15% to Rs 271 Crore  Net Profit Up 17% at Rs 147 Crore 21 July  Mylan & Biocon Announce Regulatory  Submission for Proposed Biosimilar  Pegfilgrastim Accepted for Review by  European Medicines Agency 15 July  Biocon's Insulin Glargine Launched in Japan   June 2016 23 Jun  Biocon, Quark Announce Initiation of Pivotal  Phase II/III Study of QPI-1007 in Rare Eye  Disease in India 04 Jun  Mylan and Biocon to Present Phase 3  Trastuzumab Biosimilar Data at the  American Society of Clinical Oncology  (ASCO) Annual Meeting   April 2016 26 Apr  Biocon Q4FY16 Net Profit at Rs 361 Cr  Revenue Crosses Rs 1,000 Cr; Up 17% FY  16 Revenues up 14% at Rs 3,570 Cr  Net  Profit at Rs 896 Cr   March 2016 28 Mar  Biocon's Insulin Glargine Receives  Regulatory Approval in Japan 17 Mar  Biocon Inks Co-Development &  Commercialization Agreement with Lab  PiSA for rh- Insulin in USA   February 2016 15 Feb  Biocon Gets its First Generic Formulation  Approval in EU; On Track to Launch  Rosuvastatin Tablets in FY 17   January 2016 21 Jan  Biocon Q3FY16 Net Profit Up 13% at Rs 103  Crore, EBITDA Increases 23% to Rs 209  Crore, Revenues at Rs 857 Crore, up by  10% 21 Jan  Biocon Announces Data from Key Studies  for Insulin Tregopil

Biocon Businesses Recommended sites Biocon on     Home About Us Investor Relations Media Relations Careers Site Map Contact Us Our Growth Accelerators Fact Sheet Branded Formulations Biopharmaceuticals Research Services Active Discovery Program ABLE Karnataka Vision Group on BT Syngene International Biocon Academy                   Report adverse event/side effects and product complaints               * Disclaimer            © 2018, Biocon. All Rights Reserved